Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma

IntroductionIntrahepatic cholangiocarcinoma (ICC) is a rare hepatobiliary cancer characterized by a poor prognosis and a limited response to conventional therapies. Currently chemotherapy is the only therapeutic option for patients with Stage IV ICC. Due to the poor response rate, there is an urgent...

Full description

Bibliographic Details
Main Authors:	Francesco Sabbatino, Luigi Liguori, Umberto Malapelle, Francesca Schiavi, Vincenzo Tortora, Valeria Conti, Amelia Filippelli, Giampaolo Tortora, Cristina R. Ferrone, Stefano Pepe
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Oncology
Subjects:	BAP1 precision oncology cholangio carcinoma Poly ADP ribose polymerase (PARP) inhibitor RAD21 olaparib
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.567289/full

Similar Items

PARP inhibitors are a new area in the treatment of breast cancer
by: V. P. Letyagin
Published: (2014-08-01)

Efeito do inibidor de PARP em linf ´ocitos Th17 e Treg em modelo experimental de sepse
by: Vieira, Juliana de Camargo
Published: (2019)

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
by: Paul Lesueur, et al.
Published: (2019-03-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells
by: Michelle Schacke, et al.
Published: (2019-01-01)

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
by: Azam Ghafoor, MD, et al.
Published: (2021-10-01)

A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application
by: Jeffrey Roth, et al.
Published: (2014-06-01)

Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol
by: Masatoshi Takagi, et al.
Published: (2019-01-01)

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
by: Katarzyna Rygiel
Published: (2019-11-01)

Toward a Quantitative Analysis of PARP-1 and Poly(ADP-ribosyl)ation in Cellular Senescence
by: Edmonds, Yvette M.
Published: (2014)

Approches protéomiques appliquées à l'étude de la poly(adp-ribosyl)ation
by: Gagné, Jean-Philippe
Published: (2009)

New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage
by: Zongying Gu, et al.
Published: (2019-08-01)

Strategies for structural studies of poly(ADP-ribose) glycohydrolase: Towards the validation of a novel therapeutic target
by: Botta, Davide
Published: (2010)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
by: Daniel Harrision, et al.
Published: (2020-08-01)

Effect of Partial Poly (ADP-ribose) Glycohydrolase Gene Deletion on Cellular Responses to Genotoxic Stress
by: Gao, Hong
Published: (2006)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
by: Ben Fulton, et al.
Published: (2018-01-01)

Structural implications for selective targeting of PARPs
by: Jamin D. Steffen, et al.
Published: (2013-12-01)

Rôle de la poly (ADP-ribose) polymérase-1 (PARP-1)dans la réparation de l'ADN par excision de nucléotides
by: Robu, Mihaela
Published: (2010)

PARP-1 activation regulates the DNA damage response to DNA double-strand breaks
by: Krietsch, Jana
Published: (2014)

Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
by: Xiao-Fei Chang, et al.
Published: (2021-10-01)

Analyses biochimique et protéomique de la poly(ADP-ribosyl)ation
by: Tardif, Maxime
Published: (2011)

Characterization of TCDD-inducible poly-ADP-ribose polymerase (TIPARP/ARTD14) catalytic activity
by: Gomez, A., et al.
Published: (2021)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
by: Lotte van Beek, et al.
Published: (2021-05-01)

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
by: Thomas Helleday, et al.
Published: (2012-12-01)

Chloroquine Triggers Cell Death and Inhibits PARPs in Cell Models of Aggressive Hepatoblastoma
by: Katja Eloranta, et al.
Published: (2020-07-01)

A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy
by: Shah Ashish P., et al.
Published: (2018-03-01)

Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under <i>Parg</i> Deficiency
by: Yuki Sonoda, et al.
Published: (2020-04-01)

Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
by: Ali Divan, et al.
Published: (2020-04-01)

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
by: Luis Cordero Puentes, et al.
Published: (2018-05-01)

Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients
by: Francesco Sabbatino, et al.
Published: (2021-01-01)

Ciblage thérapeutique de la poly(ADP-Ribose)Polymérase-1 (PARP-1) dans le traitement du cancer carcinoïde
by: Richard, Véronique
Published: (2011)

PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis
by: Wasyluk W, et al.
Published: (2021-05-01)

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors
by: Maciej Sobczak, et al.
Published: (2020-09-01)

Relative Quantitative Comparison between Lipotoxicity and Glucotoxicity Affecting the PARP-NAD-SIRT1 Pathway in Hepatocytes
by: Jing Pang, et al.
Published: (2013-09-01)

Inhibiting poly(ADP-ribosylation) improves axon regeneration
by: Alexandra B Byrne, et al.
Published: (2016-10-01)

Abstract P-16: Interaction of Poly(ADP-Ribose)Polymerase1 and Poly(ADP-Ribose)Polymerase2 with Nucleosome during Base Excision Repair
by: Mikhail M. Kutuzov, et al.
Published: (2019-06-01)

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
by: Andrew D. Simmons, et al.
Published: (2020-03-01)

PARP7 and Mono-ADP-Ribosylation Negatively Regulate Estrogen Receptor α Signaling in Human Breast Cancer Cells
by: Marit Rasmussen, et al.
Published: (2021-03-01)

Reversing ADP-ribosylation
by: Giuliana Katharina Moeller, et al.
Published: (2017-08-01)

Serine ADP-ribosylation reversal by the hydrolase ARH3
by: Pietro Fontana, et al.
Published: (2017-06-01)